The pain with platinum: Oxaliplatin and neuropathy

European Journal of Cancer

Volumn 43, Issue 18, 2007, Pages 2631-2633

  Kiernan, Matthew C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; PLATINUM DERIVATIVE; VOLTAGE GATED SODIUM CHANNEL;

ARTICLE; COLORECTAL CANCER; DRUG WITHDRAWAL; HUMAN; MYOKYMIA; NEUROPATHY; NEUROTOXICITY; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 36349013706     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.09.008     Document Type: Note

References (20)

1. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
2. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
3. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. J Clin Oncol 15 (2004) 229-237
4. Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: A randomized study of two different schedules of oxaliplatin. Cancer Chemoth Pharm 2007; [Epub ahead of print].
5. Kiernan M.C., and Krishnan A.V. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13 (2006) 2901-2907
6. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
7. Krishnan A.V., Goldstein D., Friedlander M., and Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32 (2005) 51-60
8. Land S.R., Kopec J.A., Cecchini R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (2007) 2205-2211
9. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., and Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56 (2006) 13-16
10. Lehky T., Leonard G.D., Wilson R.H., Grem J.L., and Floeter M.K. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle & Nerve 29 (2004) 387-392
11. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., and Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
12. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 (2001) 2293-2297
13. Gamelin E., Gamelin L., Bossi L., and Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 (2002) 21-33
14. + channel function in vivo. Clin Cancer Res 12 (2006) 4481-4484
15. Hart I.K. Acquired neuromyotonia: a new autoantibody-mediated neuronal potassium channelopathy. American Journal of the Medical Sciences 319 (2000) 209-216
16. Kiernan M.C., Hart I.K., and Bostock H. Excitability properties of motor axons in patients with spontaneous motor unit activity. Journal of Neurology, Neurosurgery & Psychiatry 70 (2001) 56-64
17. Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10 (2004) 4055-4061
18. Binder A, Stengel M, Maag R, et al. Pain in oxaliplating-induced neuropathy - Sensitisation in the peripheral and central nociceptive system. Eur J Cancer, in press. doi:10.1016/j.ejca.2007.07.030.
19. Lecomte T., Landi B., Beaune P., Laurent-Puig P., and Loriot M.-A. Glutathione s-transferase p1 polymorphism (ile105val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
20. Hochster H.S., Grothey A., and Childs B.H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol (2007) [Epub ahead of print]